Current Opinion in Virology, Год журнала: 2024, Номер 67, С. 101425 - 101425
Опубликована: Июнь 28, 2024
Язык: Английский
Scientific Reports, Год журнала: 2025, Номер 15(1)
Опубликована: Янв. 13, 2025
Abstract BCG remains the only licensed vaccine for tuberculosis (TB), but its efficacy wanes over time. Subunit vaccines, aim to improve immunity and protection, by inducing responses a few mycobacterial antigens delivered with specific platform. Since platform shapes immune response induced, selecting right has been challenging due lack of correlates protection. Recently, protein-adjuvated subunit vaccine. M72/AS01E, demonstrated 49.7% in preventing active TB latently infected adults, indicating that protective through vaccines is possible. In this study we evaluated immunogenicity promising antigen PPE15, formulated five adjuvants developed Vaccine Formulation Institute. While all were immunogenic, PPE15 LMQ protected vaccinated mice against an vivo Mycobacterium challenge, both as standalone boost BCG. Vaccinated had enriched lung parenchymal antigen-specific CD4 + CXCR3 KLRG1− T cells previously associated Heterologous vaccination strategies also explored combining intranasal ChAdOx1.PPE15 viral vector, intramuscular PPE15-LMQ resulting improved protection compared individual vaccines. These findings support progression candidate next stages development.
Язык: Английский
Процитировано
3
Vaccines, Год журнала: 2024, Номер 12(9), С. 1002 - 1002
Опубликована: Сен. 1, 2024
Traditional vaccines can be classified into inactivated vaccines, live attenuated and subunit given orally or via intramuscular (IM) injection subcutaneous (SC) for the prevention of infectious diseases. Recently, recombinant protein DNA mRNA multiple/alternative administering route (e.g., microneedle inhalation) have been developed to make more secure, effective, tolerable, universal public. In addition preventing diseases, novel currently are being prevent cure noninfectious including cancer. These vaccine platforms using various biotechnologies such as viral vectors, nanoparticles, mRNA, recombination DNA, subunit, adjuvants, other delivery systems. this review, we will explore development applying biotechnologies, based on administration routes, viruses applied cancer prevention, therapeutic vaccines.
Язык: Английский
Процитировано
4
Vaccines, Год журнала: 2025, Номер 13(5), С. 442 - 442
Опубликована: Апрель 23, 2025
Background: Tuberculosis (TB) is a respiratory infectious disease, and the current TB vaccine has low local lung protection. We aim to optimize immune pathways improve immunogenicity of vaccines. Methods: In study, 50 BALB/c mice were randomly divided into following: (1) phosphate buffered saline (PBS)+intramuscular injection combined with electroporation (EP) group (100 μL), (2) pVAX1+EP (50 μg/100 (3) ag85ab+EP (4) pVAX1+pulmonary delivery (PD) μg/50 (5) ag85ab+PD μL). Immunization was given once every 2 weeks for total three times. The number IFN-γ-secreting spleen lymphocytes determined by enzyme-linked immunospot assay (ELISPOT). levels Th1, Th2, Th17 cytokines in culture supernatants detected Luminex method. proportion FoxP3 regulatory T cells splenocytes flow cytometry. IgG-, IgG1-, IgG2a-specific antibodies plasma IgA antibody bronchoalveolar lavage fluid (BALF) immunosorbent (ELISA). Results: PD EP routes Mycobacterium tuberculosis (M. tb) ag85ab DNA can effectively induce responses lymphocytes, dominant Th1 cell responses. route earlier, greater numbers stronger pulmonary effector cells, higher specific BALF. High IgG, IgG1, IgG2α immunized route. Conclusions: vaccines more stimulate body produce strong cellular mucosal immunity than route, especially lungs, which provide early protection lungs. It significantly vaccine, suggesting feasible effective approach immunization.
Язык: Английский
Процитировано
0
Current Opinion in Virology, Год журнала: 2024, Номер 67, С. 101425 - 101425
Опубликована: Июнь 28, 2024
Язык: Английский
Процитировано
1